Pertinax Pharma Ltd is Bristol based startup developing medical and veterinary applications of novel materials that provide sustained release of chlorhexidine (CHX). A broad spectrum antiseptic, CHX is effective against a wide range of bacteria, fungi and yeasts, but the efficacy of commercial formulations of CHX is limited by the high solubility of conventional CHX salts. The CHX is rapidly depleted from the site of application by fluids, which results in an efficacy sustained for typically less than 12 hours. This limitation is overcome by Pertinax™ technology, which extends the duration of action of the CHX to weeks, months or years. The company's primary focus is the development of wound care materials and orthopaedic materials incorporating Pertinax. We welcome approaches by companies who are interested in exploring the use of Pertinax in their medical and veterinary products.